Birmingham, Alabama -- Biotechnology company PNP Therapeutics has secured $336,000 in new equity venture capital funding, according to an SEC regulatory filing.
PNP is commercializing a "unique cancer treatment approach predicated on the knowledge that solid tumors can be induced to develop their own chemotherapy in the solicit their own self-destruction."
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 14 investors participated in the offering.
Minimum investment size per investor was listed as $10,000.